<DOC>
	<DOC>NCT01376115</DOC>
	<brief_summary>To investigate safety and efficacy on Japanese subjects treated with nelarabine injection for intravenous use in clinical settings of the following diseases: 1. T-cell acute lymphocytic leukemia (T-ALL) 2. T-cell lymphoblastic lymphoma (T-LBL) Also, "any adverse events involving neurological disorder, hypotension, and blood disorder and their details" are to be investigated as an item of particular concern. In addition, subject outcome (alive or dead) at one year after the start of treatment will also be investigated.</brief_summary>
	<brief_title>Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg</brief_title>
	<detailed_description />
	<criteria>Diagnosis of Tcell acute lymphocytic leukemia (TALL) or Tcell lymphoblastic lymphoma (TLBL) Subjects with hypersensitivity to nelarabine</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>